Ekere Essien to Middle Aged
This is a "connection" page, showing publications Ekere Essien has written about Middle Aged.
Connection Strength
1.181
-
Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors. Am J Clin Oncol. 2024 Nov 01; 47(11):517-525.
Score: 0.164
-
Development and internal validation of a risk prediction model for HIV disease severity among people living with HIV and mental illness or substance use disorder. Ann Epidemiol. 2023 11; 87:79-92.
Score: 0.155
-
Public opinion regarding government response to COVID-19: case study of a large commercial city in Nigeria. Pan Afr Med J. 2021; 38:282.
Score: 0.131
-
Sources of clinical information used in HIV care and treatment: Are providers' choices related to their demographic and practice characteristics? Health Informatics J. 2019 12; 25(4):1572-1587.
Score: 0.109
-
Systemic Delays in the Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients in Houston, Texas: The Providers' Report Card. J Int Assoc Provid AIDS Care. 2018 Jan-Dec; 17:2325958218774042.
Score: 0.105
-
Managing the Personal Side of Health Care among Patients with HIV/AIDS. J Int Assoc Provid AIDS Care. 2017 Mar/Apr; 16(2):149-160.
Score: 0.094
-
Epidemiologic and behavioral characterization of knowledge of condom use and modeling among military personnel. Afr J Reprod Health. 2008 Aug; 12(2):32-44.
Score: 0.054
-
Emerging sociodemographic and lifestyle predictors of intention to use condom in human immunodeficiency virus intervention among uniformed services personnel. Mil Med. 2006 Oct; 171(10):1027-34.
Score: 0.048
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
Score: 0.042
-
Infection Risk Associated with High-Efficacy Disease-Modifying Agents in Multiple Sclerosis: A Retrospective Cohort Study. Clin Pharmacol Ther. 2025 Feb; 117(2):561-569.
Score: 0.042
-
Factors associated with the initiation of high-efficacy disease-modifying agents over moderate-efficacy disease-modifying agents in multiple sclerosis. Mult Scler Relat Disord. 2024 Nov; 91:105896.
Score: 0.042
-
Medication Adherence to Antihypertensive Triple-Combination Therapy Among Patients Enrolled in a Medicare Advantage Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):678-686.
Score: 0.029
-
A Motivational Interviewing Intervention by Pharmacy Students to Improve Medication Adherence. J Manag Care Spec Pharm. 2017 May; 23(5):549-560.
Score: 0.025
-
Comparative Effectiveness of Smoking Cessation Medications to Attenuate Weight Gain Following Cessation. Subst Use Misuse. 2016; 51(5):586-97.
Score: 0.023
-
Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers. Subst Use Misuse. 2015; 50(13):1628-37.
Score: 0.023
-
Frequency and Determinants of Preventive Care Counseling by HIV Medical Care Providers during Encounters with Newly Diagnosed and Established HIV-Infected Patients. J Int Assoc Provid AIDS Care. 2016 05; 15(3):215-27.
Score: 0.021
-
System and Patient Barriers to Care among People Living with HIV/AIDS in Houston/Harris County, Texas: HIV Medical Care Providers' Perspectives. J Int Assoc Provid AIDS Care. 2015 Nov-Dec; 14(6):505-15.
Score: 0.020
-
The relationship between obesity and prescription of smoking cessation medications. Popul Health Manag. 2014 Jun; 17(3):172-9.
Score: 0.020
-
Predictors of smoking cessation medication use among nonobese and obese smokers. Subst Use Misuse. 2014 May; 49(6):752-61.
Score: 0.020
-
The impact of Medicare Part D on psychotropic utilization and financial burden for community-based seniors. Psychiatr Serv. 2008 Oct; 59(10):1191-7.
Score: 0.014